Fibromyalgia Causes: What Triggers Central Sensitization and Why Some People Are More Vulnerable

Fibromyalgia has no single cause: it develops when an inherited tendency toward pain amplification meets a trigger such as physical injury, infection, surgery or prolonged stress, and the brain and spinal cord stay locked in a state called central sensitization. Twin and family studies attribute roughly 50% of the risk to genes, and first-degree relatives of people with fibromyalgia are about 8 times more likely to develop it, according to Arnold and colleagues (2004).

Fibromyalgia Is Not “Just Pain”

For decades, fibromyalgia was dismissed as psychosomatic, a wastebasket diagnosis for patients whose pain couldn’t be explained by standard testing. That view has been thoroughly dismantled by two decades of neuroscience, immunology and genetics research. Fibromyalgia is a disorder of pain processing with measurable biological underpinnings.

The condition goes by several names. Older literature calls it fibrositis, many papers use fibromyalgia syndrome (FMS), and the fibromyalgia condition overview covers its core symptoms: chronic widespread pain, fatigue, unrefreshing sleep and cognitive problems often called fibro fog. The question is no longer whether it’s real, but rather how the nervous system gets locked into this state and why it happens to some people and not others.

The short answer: there is no single cause. Fibromyalgia arises when a genetically susceptible nervous system encounters a triggering event, or an accumulation of events, that pushes pain processing circuits into a self-reinforcing state of hyperexcitability. Understanding these components matters because it points toward more targeted and effective treatment strategies.

What Causes Fibromyalgia? The Main Contributing Factors

Fibromyalgia is caused by a combination of inherited vulnerability, a triggering event and ongoing biological processes that keep pain amplification switched on. Researchers group these contributors into the categories below. Most patients have more than one, and the mix differs from person to person.

The table is a map, not a ranking: a factor with emerging evidence can still be the dominant driver for one person.

Central Sensitization: The Core Mechanism

Central sensitization is the neurological process at the heart of fibromyalgia. In a normally functioning nervous system, pain signals from the body are processed, modulated and filtered. Not every signal makes it to conscious awareness, and the brain adjusts the “volume” of incoming pain signals based on context, as Clifford Woolf of Harvard Medical School described in his 2011 review [1].

In central sensitization, this modulation system breaks down in two ways:

• Amplified excitation: The spinal cord and brain become hyperexcitable, magnifying incoming pain signals. Stimuli that normally register as mild pressure or temperature now register as pain (allodynia). Stimuli that are mildly painful become severely painful (hyperalgesia).
• Impaired inhibition: The descending pain inhibitory pathways, which normally dampen pain signals, become less effective. Think of it as losing the brakes on a car that’s simultaneously hitting the accelerator.

Functional MRI studies show that fibromyalgia patients have increased activation in brain regions that process pain (the insula, anterior cingulate cortex and somatosensory cortex) when exposed to stimuli that healthy controls find non-painful. Gracely, Clauw and colleagues first showed this in 2002. This isn’t imagined pain. It’s documented, measurable neural hyperactivity [2].

The neurotransmitter picture supports this model. Fibromyalgia patients have elevated levels of excitatory neurotransmitters like glutamate and substance P in their cerebrospinal fluid, and reduced levels of inhibitory neurotransmitters like serotonin, norepinephrine and GABA. This neurochemical imbalance directly explains why SNRIs (which boost serotonin and norepinephrine) and pregabalin (which reduces excitatory neurotransmitter release) are effective treatments for some patients [3].

What is nociplastic pain?

Nociplastic pain is pain that arises from altered pain processing rather than from tissue damage (nociceptive pain) or nerve injury (neuropathic pain). The International Association for the Study of Pain (IASP) adopted the term in 2017, and fibromyalgia is its prototype. In his 2014 clinical review in JAMA, Daniel Clauw describes fibromyalgia as a centralized pain state that often travels with related conditions [16].

Muhammad Yunus grouped these related conditions as central sensitivity syndromes. The group includes irritable bowel syndrome, temporomandibular disorder, migraine and tension headache, interstitial cystitis and chronic fatigue syndrome (ME/CFS). Having one raises the odds of developing another, which is one reason a broad chronic pain history matters at diagnosis.

Genetic Vulnerability

Fibromyalgia runs in families. First-degree relatives of fibromyalgia patients are 8 times more likely to develop the condition than the general population, according to a family study by Lesley Arnold and colleagues (2004). Twin studies estimate that genetic factors account for approximately 50% of the risk, with environmental factors accounting for the other half [4].

The genetic landscape is not a single “fibromyalgia gene” but rather a collection of polymorphisms that affect pain processing, stress response and neurotransmitter metabolism:

• COMT (catechol-O-methyltransferase): The Val158Met polymorphism reduces the enzyme’s ability to break down catecholamines (dopamine, norepinephrine, epinephrine). The low-activity “Met” variant is associated with higher pain sensitivity and increased fibromyalgia risk [5].
• Serotonin transporter gene (SLC6A4): The short allele of the 5-HTTLPR polymorphism reduces serotonin reuptake efficiency and is more common in fibromyalgia patients.
• SCN9A: This gene encodes a sodium channel (Nav1.7) critical for pain signaling. Variants in SCN9A are associated with altered pain sensitivity across multiple chronic pain conditions, including fibromyalgia [6].
• HLA associations: Some studies have found increased prevalence of certain HLA (human leukocyte antigen) types in fibromyalgia, hinting at an immune-genetic component.

What this means practically: you don’t inherit fibromyalgia itself. You inherit a nervous system that’s more susceptible to developing central sensitization when exposed to the right (or wrong) triggers. This is why two people can experience the same car accident and one develops widespread chronic pain while the other recovers fully.

Triggering Events

Most fibromyalgia patients can identify a precipitating event or period that preceded symptom onset. The CDC lists stressful or traumatic events, accidents, repeated injuries and illnesses such as viral infections as recognized risk factors or triggers [17]. The most commonly identified triggers include:

Physical Trauma

Motor vehicle accidents, surgeries and physical injuries are among the most frequently reported triggers. In a controlled study of 161 injured patients, Dan Buskila and colleagues found fibromyalgia in 21.6% of people with neck (whiplash-type) injuries versus 1.7% of people with leg fractures, a rate more than 10 times higher, diagnosed at a mean of 3.2 months after the injury [7]. The hypothesis is that the combination of tissue injury, pain signaling, inflammatory mediators and psychological distress creates a “perfect storm” that tips a vulnerable nervous system into central sensitization.

Infections

Several infections have been linked to fibromyalgia onset:

• Epstein-Barr virus (EBV): The virus that causes mononucleosis. Post-infectious fatigue and pain syndromes following EBV are well-documented, and some progress to meet full fibromyalgia criteria [8].
• Lyme disease: Post-treatment Lyme disease syndrome (PTLDS) shares significant symptom overlap with fibromyalgia, and some patients initially diagnosed with PTLDS eventually receive a fibromyalgia diagnosis. The Lyme disease condition page covers testing and persistent symptoms.
• Hepatitis C: Chronic hepatitis C infection is associated with a significantly elevated risk of fibromyalgia, possibly through direct effects on the nervous system or chronic immune activation.
• COVID-19: Long COVID has emerged as a significant trigger for new-onset fibromyalgia. Studies report that 30-40% of long COVID patients meet fibromyalgia diagnostic criteria, suggesting that SARS-CoV-2 can trigger central sensitization through neuroinflammatory mechanisms [9].

The common thread is that acute infection triggers a cascade of inflammatory cytokines, microglial activation and immune dysregulation that, in a genetically susceptible individual, doesn’t fully resolve after the infection clears.

Psychological Trauma and Chronic Stress

Adverse childhood experiences (ACEs), post-traumatic stress disorder (PTSD) and chronic psychological stress are strongly associated with fibromyalgia. A meta-analysis by Winfried Häuser and colleagues (2011) found that individuals who experienced childhood physical or sexual abuse had a 2-3 fold increased risk of developing fibromyalgia in adulthood [10].

The mechanism isn’t purely psychological. Chronic stress and trauma produce measurable changes in the hypothalamic-pituitary-adrenal (HPA) axis, autonomic nervous system and central pain processing. Prolonged cortisol dysregulation alters neuroplasticity and immune function in ways that prime the nervous system for central sensitization. The brain’s threat detection system, already calibrated to high alert by trauma, begins interpreting normal sensory input as dangerous, including pain signals.

Hormonal Transitions

Fibromyalgia is 2-3 times more common in women than men, and many female patients report symptom onset during hormonal transition periods: puberty, postpartum, perimenopause, or after hysterectomy. Estrogen has modulatory effects on pain processing, serotonin synthesis and microglial activation. Declining or fluctuating estrogen levels may reduce the nervous system’s pain inhibition capacity, lowering the threshold for central sensitization [11].

Sleep Disruption

Poor sleep is both a symptom and a likely contributor. In a classic 1975 experiment, Harvey Moldofsky and colleagues in Toronto disrupted deep non-REM sleep in healthy volunteers and produced musculoskeletal aching and tenderness that resembled the condition then called fibrositis [18]. Chronic insomnia and untreated obstructive sleep apnea can keep pain thresholds low, which is why sleep assessment belongs in any workup.

Neuroinflammation: The Immune-Brain Connection

One of the most significant advances in fibromyalgia research has been the recognition that neuroinflammation plays a central role. Microglia, the immune cells of the central nervous system, are activated in fibromyalgia patients.

A landmark 2019 PET imaging study led by Daniel Albrecht and Marco Loggia at Massachusetts General Hospital, with collaborators at Karolinska Institutet, used a radiotracer that binds to activated glial cells and demonstrated widespread neuroinflammation in fibromyalgia patients compared to healthy controls. The degree of glial activation correlated with fatigue severity [12].

This finding bridged a gap in the field. Central sensitization had been well-established, but the driving force behind it was unclear. Neuroinflammation, fueled by activated microglia releasing pro-inflammatory cytokines and excitatory mediators, provides a plausible upstream mechanism.

This also helps explain why therapies that target microglial activation, such as low-dose naltrexone (LDN), show benefit in some fibromyalgia patients. LDN is thought to modulate microglial activity, reducing the neuroinflammatory cascade that sustains central sensitization. LDN is used off label for fibromyalgia, and the trials so far are small.

In a 2013 crossover trial at Stanford, Jarred Younger and colleagues gave 4.5 mg of naltrexone nightly and reported a 28.8% reduction in baseline pain on LDN versus 18.0% on placebo [19]. A 2023 Danish randomized crossover trial of 58 patients, published in Pain Reports by Bested and colleagues, found no clinically relevant pain relief over placebo [20]. The guide to LDN for fibromyalgia covers dosing, side effects and what larger trials are testing.

Is Fibromyalgia an Autoimmune Disease?

Fibromyalgia is not classified as an autoimmune disease, but a growing line of research suggests that antibodies may drive pain in some patients. In a 2021 study in the Journal of Clinical Investigation, Andreas Goebel of the University of Liverpool, with teams at King’s College London and Karolinska Institutet, injected mice with immunoglobulin G (IgG) antibodies taken from fibromyalgia patients [21].

The mice developed heightened sensitivity to pressure and cold, weaker grip strength and a loss of nerve fibers in the skin. The patient antibodies bound to satellite glial cells and neurons in the dorsal root ganglia, the clusters of sensory nerve cells beside the spinal cord. Mice given IgG from healthy people showed no change, and the authors suggest that therapies lowering antibody levels deserve testing.

This is early, animal-model evidence, and no antibody test for fibromyalgia exists. Autoimmune diseases such as rheumatoid arthritis and lupus do co-occur with fibromyalgia at higher rates, so screening for them remains a standard part of evaluation.

Small Fiber Neuropathy: A Peripheral Component

While fibromyalgia has traditionally been viewed as a purely central disorder, research over the past decade has revealed that many patients have objectively measurable peripheral nerve damage. Skin punch biopsy studies find reduced intraepidermal nerve fiber density (IENFD) in a large share of fibromyalgia patients, meeting the diagnostic criteria for small fiber neuropathy (SFN), also called small-fiber polyneuropathy [13].

In the best-known study, Anne Louise Oaklander and colleagues at Massachusetts General Hospital found that 41% of skin biopsies from fibromyalgia patients were diagnostic for small-fiber polyneuropathy, compared with 3% from matched controls. Some of those patients had identifiable underlying causes, including immune markers and hepatitis C [13].

Small fiber nerves transmit pain and temperature signals and control autonomic functions. Their loss or damage could contribute to:

• Peripheral pain generation that feeds into and reinforces central sensitization
• Autonomic symptoms (temperature dysregulation, sweating abnormalities, GI motility issues)
• The burning, tingling, or “pins and needles” sensations that many fibromyalgia patients describe

This finding is clinically relevant because it suggests that fibromyalgia isn’t exclusively a brain problem. There’s a real, measurable peripheral nerve pathology in a significant subset of patients. Testing for SFN (skin punch biopsy or specialized nerve testing like QSART and sudomotor testing), usually ordered by a neurologist, may be worth pursuing, especially in patients with prominent neuropathic pain features. The small fiber neuropathy guide explains how the biopsy works.

The Gut-Brain Axis

The relationship between the gut microbiome and fibromyalgia has moved from speculation to documented science. A 2019 study published in Pain by Amir Minerbi and colleagues at McGill University found that fibromyalgia patients had significantly altered gut microbiome composition compared to healthy controls. Specific bacterial species were correlated with pain severity, and the researchers could distinguish fibromyalgia patients from controls based on microbiome analysis alone with 87% accuracy [14].

The gut-brain connection in fibromyalgia likely operates through several pathways:

• Immune activation: Dysbiosis (microbial imbalance) increases intestinal permeability (“leaky gut”), allowing bacterial components like lipopolysaccharide (LPS) to enter the bloodstream and trigger systemic inflammation.
• Neurotransmitter production: Gut bacteria produce or influence the production of serotonin, GABA and dopamine. Altered microbial composition directly affects the neurochemistry of pain modulation.
• Vagus nerve signaling: The gut communicates with the brain through the vagus nerve. Dysbiotic gut flora generate aberrant vagal signaling that can influence central pain processing.
• Short-chain fatty acid production: Beneficial bacteria produce butyrate and other short-chain fatty acids that have anti-inflammatory effects. Reduced production may contribute to both gut and systemic inflammation.

This research opens the door to microbiome-targeted therapies. Specific probiotic protocols for fibromyalgia haven’t been established in large trials, and the Minerbi study shows association rather than cause. Optimizing gut health through dietary fiber, fermented foods and targeted probiotics is a reasonable and low-risk component of a comprehensive management strategy, particularly for people who also have irritable bowel syndrome.

Autonomic Dysfunction

Autonomic nervous system dysfunction is present in the majority of fibromyalgia patients. Heart rate variability (HRV) studies consistently show reduced vagal tone and sympathetic predominance, meaning the “fight or flight” branch of the autonomic nervous system is chronically overactive while the “rest and digest” branch is underperforming. Manuel Martinez-Lavin of the National Institute of Cardiology in Mexico City has described fibromyalgia as a sympathetically maintained pain syndrome [15].

This sympathetic overdrive contributes to:

• Sleep disruption (the nervous system is too activated to transition smoothly into deep sleep)
• Widespread muscle tension and pain (sustained sympathetic activation increases muscle tone)
• Fatigue (the body is burning energy maintaining a state of hypervigilance)
• Cognitive dysfunction (sympathetic dominance impairs prefrontal cortex function)
• GI symptoms (sympathetic activation slows gut motility)

Overlap with POTS (postural orthostatic tachycardia syndrome) is common. Some studies report that up to 70% of fibromyalgia patients have orthostatic intolerance on tilt-table testing. Whether autonomic dysfunction is a cause, consequence, or co-occurring feature of fibromyalgia is still debated.

Addressing it through vagal toning exercises, breathing techniques, and beta-blockers or other autonomic-modulating medications often produces meaningful symptom improvement. HRV biofeedback trains slower breathing and higher heart rate variability; the biofeedback therapy guide explains sessions, and you can compare biofeedback clinics across the US. Trials of biofeedback in fibromyalgia are small, so treat it as one tool alongside others. The dysautonomia treatment overview covers the medical side.

Risk Factors: Who Gets Fibromyalgia?

Based on the research, and consistent with the CDC’s list of people more likely to develop fibromyalgia [17], the highest-risk profile includes:

• Sex: Female (2-3x higher risk, though male fibromyalgia is underdiagnosed)
• Age: Peak onset between 30-50 years old, though it can develop at any age, including in children
• Family history: First-degree relative with fibromyalgia or another chronic pain condition
• History of trauma: Physical trauma (especially whiplash), childhood adverse experiences, PTSD
• Other pain conditions: Pre-existing conditions like IBS, TMJ disorder, endometriosis, or chronic headaches (central sensitization conditions tend to cluster)
• Sleep disorders: Chronic insomnia or untreated sleep apnea
• Autoimmune disease: Rheumatoid arthritis, lupus and other autoimmune conditions frequently co-occur with fibromyalgia
• Obesity: Adipose tissue produces inflammatory cytokines, and mechanical loading increases peripheral pain input. Weight management may reduce fibromyalgia severity in some patients.

How Is Fibromyalgia Diagnosed?

Fibromyalgia is diagnosed clinically, from a symptom history and examination, because no blood test or scan confirms it. Most US clinicians use criteria from the American College of Rheumatology (ACR), first published by Frederick Wolfe and colleagues in 2010 and revised in 2016 [22][23]. The older 1990 tender point count has been replaced by two scores: the Widespread Pain Index (WPI, 0 to 19 body areas) and the Symptom Severity Scale (SSS, 0 to 12).

In US medical records, fibromyalgia is coded as M79.7 in ICD-10-CM. Primary care physicians and rheumatologists make most diagnoses, and a rheumatologist is the usual referral when the picture is unclear.

Which conditions can look like fibromyalgia?

Several treatable conditions cause widespread pain and fatigue. Clinicians commonly check a complete blood count, inflammatory markers (ESR and CRP) and thyroid function (TSH), and may test vitamin D or screen for autoimmune disease. Conditions worth ruling out include:

• Hypothyroidism, including Hashimoto’s thyroiditis
• Inflammatory arthritis, such as rheumatoid arthritis, and systemic lupus erythematosus
• Polymyalgia rheumatica, mainly in adults over 50
• Small fiber neuropathy and other neuropathies
• Sleep apnea and other primary sleep disorders
• Medication effects, such as statin-associated muscle symptoms

Finding one of these does not rule out fibromyalgia: under the 2016 criteria the two can coexist.

Why Understanding Causes Matters for Treatment

Knowing what’s driving your fibromyalgia changes how you treat it. If neuroinflammation is prominent, LDN or other microglial modulators make sense. If gut dysbiosis is a major contributor, microbiome restoration is a priority. If autonomic dysfunction is severe, vagal toning and autonomic-modulating strategies should be part of the plan. If a specific trauma triggered the onset, trauma-informed therapy (EMDR, somatic experiencing) may address a root cause that medications alone cannot.

Fibromyalgia is not one disease with one cause. It’s a final common pathway that different combinations of genetic, environmental and physiological factors can converge upon. The most effective treatment plans account for this complexity and target the specific contributing factors present in each individual patient.

Which treatments match which drivers?

The table links each driver to the approaches clinicians commonly use for it and to how strong the evidence is. The 2017 EULAR revised recommendations, led by Gary Macfarlane of the University of Aberdeen, gave exercise the only “strong for” rating; every other therapy was rated “weak for” [24].

Many integrative and regenerative clinics also offer therapies such as ketamine infusions, IV nutrient drips or hyperbaric oxygen for fibromyalgia. These are generally cash pay, not FDA approved for fibromyalgia, and supported mostly by small studies. The fibromyalgia treatment guide compares conventional and integrative options, and the chronic pain treatment overview covers approaches shared across pain conditions.

Who treats fibromyalgia?

Fibromyalgia care is usually shared. A primary care physician or rheumatologist confirms the diagnosis and manages medication. Pain medicine physicians, neurologists (for suspected small fiber neuropathy), sleep specialists, physical therapists and psychologists trained in CBT each handle part of the plan.

When you compare clinics on Regenerated.com, the list order is not a paid ranking, and Featured slots are clearly labeled and capped. A Verified badge means the clinic completed our credential checks; it is not something a clinic can buy. Regenerated.com is free for patients, and appearing in the directory is not an endorsement. The guide to Featured, Verified and organic listings explains each label.

Frequently asked questions

What is the main cause of fibromyalgia?

The main cause of fibromyalgia is central sensitization, a change in how the brain and spinal cord process pain so that normal signals are amplified and inhibition is weakened. It usually develops when an inherited vulnerability, which accounts for about half of the risk, meets a trigger such as injury, infection, surgery or prolonged stress. Neuroinflammation, poor sleep, autonomic imbalance and small fiber nerve damage can help keep the process going.

Can stress or trauma cause fibromyalgia?

Stress and trauma do not cause fibromyalgia on their own, but they are among its strongest risk factors. A 2011 meta-analysis by Häuser and colleagues linked childhood physical and sexual abuse with a higher risk of fibromyalgia in adulthood. Chronic stress changes the HPA axis and autonomic nervous system in ways that lower pain thresholds. That is a biological effect, not a sign that the pain is imagined.

Can a virus trigger fibromyalgia?

Yes, viral and other infections are recognized triggers of fibromyalgia. Epstein-Barr virus, hepatitis C, Lyme disease and COVID-19 have all been linked to new-onset cases, and a 2021 survey by Ursini and colleagues found that a substantial share of people with long COVID met fibromyalgia criteria. The leading explanation is that immune activation and neuroinflammation persist after the infection clears in people who are already genetically susceptible.

Is fibromyalgia genetic or hereditary?

Fibromyalgia is partly genetic. A family study by Arnold and colleagues (2004) found that first-degree relatives of patients were about 8 times more likely to have the condition, and twin research puts the genetic share of risk at roughly 50%. People inherit a more sensitive pain system, shaped by genes such as COMT, SLC6A4 and SCN9A, rather than the disease itself. No genetic test can diagnose fibromyalgia.

Is fibromyalgia an autoimmune disease?

Fibromyalgia is not currently classified as an autoimmune disease, but research suggests antibodies may play a role in some patients. In a 2021 study in the Journal of Clinical Investigation, Goebel and colleagues showed that IgG antibodies from fibromyalgia patients made mice more sensitive to pain. That finding comes from an animal model and has not yet led to a test or approved treatment, so it remains an active research question.

Related Reading

• Fibromyalgia: Understanding Central Sensitization and Your Treatment Options (Pillar)
• Fibromyalgia Treatment: Medications, Lifestyle Changes, and Emerging Therapies That Actually Help
• Chronic Fatigue Syndrome Treatment: What Helps and What Doesn’t
• Dysautonomia Symptoms: Recognizing Autonomic Nervous System Dysfunction
• Leaky Gut Symptoms: What the Science Actually Supports
• POTS Treatment: Managing Postural Orthostatic Tachycardia Syndrome

Sources

1. Woolf CJ. Central sensitization: implications for the diagnosis and treatment of pain. Pain. 2011;152(3 Suppl):S2-S15. doi:10.1016/j.pain.2010.09.030 ↩
2. Gracely RH, Petzke F, Wolf JM, Clauw DJ. Functional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia. Arthritis Rheum. 2002;46(5):1333-1343. doi:10.1002/art.10225 ↩
3. Russell IJ, Vaeroy H, Javors M, Nyberg F. Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis. Arthritis Rheum. 1992;35(5):550-556. doi:10.1002/art.1780350509 ↩
4. Arnold LM, Hudson JI, Hess EV, et al. Family study of fibromyalgia. Arthritis Rheum. 2004;50(3):944-952. doi:10.1002/art.20042 ↩
5. Gursoy S, Erdal E, Herken H, et al. Significance of catechol-O-methyltransferase gene polymorphism in fibromyalgia syndrome. Rheumatol Int. 2003;23(3):104-107. doi:10.1007/s00296-002-0257-5 ↩
6. Vargas-Alarcon G, Alvarez-Leon E, Fragoso JM, et al. A SCN9A gene-encoded dorsal root ganglia sodium channel polymorphism associated with severe fibromyalgia. BMC Musculoskelet Disord. 2012;13:23. doi:10.1186/1471-2474-13-23 ↩
7. Buskila D, Neumann L, Vaisberg G, Alkalay D, Wolfe F. Increased rates of fibromyalgia following cervical spine injury. A controlled study of 161 cases of traumatic injury. Arthritis Rheum. 1997;40(3):446-452. doi:10.1002/art.1780400310 ↩
8. Hickie I, Davenport T, Wakefield D, et al. Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens: prospective cohort study. BMJ. 2006;333(7568):575. doi:10.1136/bmj.38933.585764.AE ↩
9. Ursini F, Ciaffi J, Mancarella L, et al. Fibromyalgia: a new facet of the post-COVID-19 syndrome spectrum? Results from a web-based survey. RMD Open. 2021;7(3):e001735. doi:10.1136/rmdopen-2021-001735 ↩
10. Hauser W, Kosseva M, Uceyler N, Klose P, Sommer C. Emotional, physical, and sexual abuse in fibromyalgia syndrome: a systematic review with meta-analysis. Arthritis Care Res. 2011;63(6):808-820. doi:10.1002/acr.20328 ↩
11. Craft RM. Modulation of pain by estrogens. Pain. 2007;132(Suppl 1):S3-S12. doi:10.1016/j.pain.2007.09.028 ↩
12. Albrecht DS, Forsberg A, Sandstrom A, et al. Brain glial activation in fibromyalgia: a multi-site positron emission tomography investigation. Brain Behav Immun. 2019;75:72-83. doi:10.1016/j.bbi.2018.09.018 ↩
13. Oaklander AL, Herzog ZD, Downs HM, Klein MM. Objective evidence that small-fiber polyneuropathy underlies some illnesses currently labeled as fibromyalgia. Pain. 2013;154(11):2310-2316. doi:10.1016/j.pain.2013.06.001 ↩
14. Minerbi A, Gonzalez E, Brereton NJ, et al. Altered microbiome composition in individuals with fibromyalgia. Pain. 2019;160(11):2589-2602. doi:10.1097/j.pain.0000000000001640 ↩
15. Martinez-Lavin M. Fibromyalgia as a sympathetically maintained pain syndrome. Curr Pain Headache Rep. 2004;8(5):385-389. doi:10.1007/s11916-996-0012-4 ↩
16. Clauw DJ. Fibromyalgia: a clinical review. JAMA. 2014;311(15):1547-1555. doi:10.1001/jama.2014.3266 ↩
17. Centers for Disease Control and Prevention. Fibromyalgia. cdc.gov/arthritis/fibromyalgia ↩
18. Moldofsky H, Scarisbrick P, England R, Smythe H. Musculoskeletal symptoms and non-REM sleep disturbance in patients with “fibrositis syndrome” and healthy subjects. Psychosom Med. 1975;37(4):341-351. ↩
19. Younger J, Noor N, McCue R, Mackey S. Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels. Arthritis Rheum. 2013;65(2):529-538. doi:10.1002/art.37734 ↩
20. Bested K, Jensen LM, Andresen T, et al. Low-dose naltrexone for treatment of pain in patients with fibromyalgia: a randomized, double-blind, placebo-controlled, crossover study. Pain Rep. 2023;8(4):e1080. doi:10.1097/PR9.0000000000001080 ↩
21. Goebel A, Krock E, Gentry C, et al. Passive transfer of fibromyalgia symptoms from patients to mice. J Clin Invest. 2021;131(13):e144201. doi:10.1172/JCI144201 ↩
22. Wolfe F, Clauw DJ, Fitzcharles MA, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res. 2010;62(5):600-610. doi:10.1002/acr.20140 ↩
23. Wolfe F, Clauw DJ, Fitzcharles MA, et al. 2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria. Semin Arthritis Rheum. 2016;46(3):319-329. doi:10.1016/j.semarthrit.2016.08.012 ↩
24. Macfarlane GJ, Kronisch C, Dean LE, et al. EULAR revised recommendations for the management of fibromyalgia. Ann Rheum Dis. 2017;76(2):318-328. doi:10.1136/annrheumdis-2016-209724 ↩